5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329–360. 6. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331(6024): 1565–1570. 7 . V e s e l yM D ,K e r s h a wM H ,S c h r e i b e rR D ,S m y t hM J .N a t u r a l innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235–271. 8. Chen DS, Mellman I. Elements of cancer immunity and the cancer- immune set point. Nature 2017; 541(7637): 321–330. 9. Melero I, Gaudernack G, Gerritsen W et al. Therapeutic vaccines for can- cer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11(9): 509–524. 10. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371(23): 2189–2199. 11. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350(6257): 207–211.